Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study

Honghu Tang; Eva Dokoupilová; Bogdan Batko; Marek Zawadzki; Анастас Баталов; Liu Y; Xiaolei Yang; Yinbo Zhou; Qingfeng Dong; Liu Y

doi:10.1080/14712598.2026.2663826

April 22, 2026Expert Opinion on Biological Therapy

Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to compare the efficacy and safety of the biosimilar BAT2506 to the reference drug golimumab in treating active psoriatic arthritis.
Phase 3, multicenter, double-blind, randomized, parallel-group study with patients diagnosed with active psoriatic arthritis.
Patients received either BAT2506 or golimumab over a 24-week period.
Study registered under NCT05046431.
BAT2506 demonstrated comparable efficacy to golimumab, with significant improvements in disease activity measures.
Safety profiles were similar between BAT2506 and golimumab, with no unexpected adverse events reported.
Detailed statistical outcomes are pending further analysis.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Randomized trial compares efficacy and safety of BAT2506 with golimumab in patients with psoriatic arthritis, suggesting potential alternatives for treatment.

Abstract

https://www.clinicaltrials.govidentifier NCT05046431.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tang et al. (2026) studied this question.

synapsesocial.com/papers/69ec5b3d88ba6daa22dacda7 https://doi.org/10.1080/14712598.2026.2663826

View at Publisher

Ask AI

Bookmark

Share

Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Expert Opinion on Biological Therapy

Keep reading

More related papers

More from Expert Opinion on Biological Therapy